Abstract
The relaxin family peptide receptor 1 (RXFP1) is the receptor for relaxin-2, an important regulator of reproductive and cardiovascular physiology. RXFP1 is a multi-domain G protein-coupled receptor (GPCR) with an ectodomain consisting of an LDLa module and leucine-rich repeats. The mechanism of RXFP1 signal transduction is clearly distinct from that of other GPCRs, but remains very poorly understood. Here, we present the cryo-electron microscopy structure of active-state human RXFP1, bound to a single-chain version of the endogenous agonist relaxin-2 and to the heterotrimeric $G_s$ protein. Evolutionary coupling analysis and structure-guided functional experiments reveal that RXFP1 signals through a mechanism of autoinhibition, wherein the receptor’s extracellular loop 2 occupies the orthosteric site in the active state but is inhibited by the ectodomain in the absence of relaxin-2. Our results explain how an unusual GPCR family functions, providing a path to rational drug development targeting the relaxin receptors.
Introduction
The relaxin family peptide receptor 1 (RXFP1) is a critical mediator of human physiology, influencing cardiovascular health and tissue remodeling during pregnancy. As a member of the leucine-rich repeat-containing (LGR) family of G protein-coupled receptors (GPCRs), RXFP1 possesses a complex architecture including an N-terminal LDLa module and a large leucine-rich repeat (LRR) domain.
Unlike other LGRs activated by large glycoprotein hormones via mechanical "push-pull" forces, RXFP1 responds to the relatively small (6 kDa) hormone relaxin-2. The role of the essential LDLa module and the precise mechanism by which such a small ligand triggers signaling across the massive ectodomain have remained elusive. This study utilizes high-resolution structural biology to uncover an unconventional "autoinhibition" mechanism of activation.
Structural Determination of the Active RXFP1 Complex
To resolve the signaling mechanism, researchers determined the cryo-electron microscopy (cryo-EM) structure of the active-state human RXFP1 complex. The complex included an engineered single-chain relaxin-2 agonist and a heterotrimeric $G_s$ protein, stabilized by a "mini-$G_s$" fusion and Nanobody 35 (Nb35).
The team achieved a 3.2 Å resolution map of the transmembrane (7TM) domain and G protein interface. While the LDLa module proved too flexible for high-resolution imaging, the core signaling machinery was clearly defined, revealing how the receptor transitions to an active state.
Key Insights: The Tethered Agonist and Autoinhibition
The most significant finding is that RXFP1 utilizes its own extracellular loop 2 (ECL2) as an internal, tethered agonist. In the active state, ECL2 inserts deep into the 7TM bundle to trigger G protein coupling.
In the resting state, the receptor is "self-inhibited." The large LRR domain and a specific "hinge" region physically block ECL2 from entering the orthosteric signaling pocket. Relaxin-2 does not directly contact the signaling core; instead, it binds to the LRR domain, inducing a conformational shift that "unblocks" the ECL2 loop, allowing it to drop into the pocket and activate the receptor.
Functional Validation
Mutagenesis experiments confirmed this model. Deleting the LRR "lid" resulted in constitutive activity, where the receptor signals even without relaxin-2. Conversely, mutating critical residues in the ECL2 loop—specifically Phe564 and Leu566—completely abolished signaling, identifying them as the primary "triggers" for activation. The study also highlighted a conserved CΦPΦ motif in ECL2, suggesting this tethered agonist mechanism may be a universal feature across the LGR receptor family.
Conclusion
This work redefines our understanding of LGR signaling, moving away from simple ligand-induced activation toward a model of regulated autoinhibition. While the exact docking site of the essential LDLa module remains a subject for future study due to its high mobility, these structural insights provide a robust framework for the rational design of small-molecule drugs that could bypass the complex ectodomain to treat cardiovascular and fibrotic diseases.
Summary updated